1.Pancreas cancer - Is chemotherapy necessary?.
Korean Journal of Medicine 1999;57(4):740-749
No abstract available.
Drug Therapy*
;
Pancreas*
;
Pancreatic Neoplasms*
2.Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20.
The Korean Journal of Gastroenterology 2018;71(4):244-245
No abstract available.
Drug Therapy*
;
Humans
;
Pancreatic Neoplasms*
3.Long Term Complete Response of Unresectable Locally Advanced Pancreatic Cancer after CCRT and Gemcitabine Chemotherapy.
Jaeyun YANG ; Taekyu LIM ; Taegyoon KIM ; Seungmoon HAN ; Sanghee LEE ; Huiseo KIM ; Jiwon LEE ; Seongyeong AHN
Korean Journal of Pancreas and Biliary Tract 2016;21(4):209-215
Locally advanced or metastatic disease accounts for two thirds of total patients with pancreatic cancer. Patients with pancreatic cancer are assessed as resectable, potentially resectable (borderline) or unresectable according to pre-operative examinations. The chances of resectability may be enhanced by using neoadjuvant systemic chemotherapy, radiotherapy or both. This case report presents a locally advanced pancreatic adenocarcinoma that was identified to be unresectable during surgical exploration. After receiving concurrent chemoradiotherapy, the patient was re-evaluated, identified as unresectable and received gemcitabine maintenance chemotherapy. Herein, we report the case of a patient with unresectable locally advanced pancreatic adenocarcinoma who achieved a complete response lasting for more than 32 months after receiving concurrent chmoradiotherapy followed by gemcitabine maintenance chemotherapy.
Adenocarcinoma
;
Chemoradiotherapy
;
Drug Therapy*
;
Humans
;
Maintenance Chemotherapy
;
Pancreatic Neoplasms*
;
Radiotherapy
4.Long Term Complete Response of Unresectable Locally Advanced Pancreatic Cancer after CCRT and Gemcitabine Chemotherapy.
Jaeyun YANG ; Taekyu LIM ; Taegyoon KIM ; Seungmoon HAN ; Sanghee LEE ; Huiseo KIM ; Jiwon LEE ; Seongyeong AHN
Korean Journal of Pancreas and Biliary Tract 2016;21(4):209-215
Locally advanced or metastatic disease accounts for two thirds of total patients with pancreatic cancer. Patients with pancreatic cancer are assessed as resectable, potentially resectable (borderline) or unresectable according to pre-operative examinations. The chances of resectability may be enhanced by using neoadjuvant systemic chemotherapy, radiotherapy or both. This case report presents a locally advanced pancreatic adenocarcinoma that was identified to be unresectable during surgical exploration. After receiving concurrent chemoradiotherapy, the patient was re-evaluated, identified as unresectable and received gemcitabine maintenance chemotherapy. Herein, we report the case of a patient with unresectable locally advanced pancreatic adenocarcinoma who achieved a complete response lasting for more than 32 months after receiving concurrent chmoradiotherapy followed by gemcitabine maintenance chemotherapy.
Adenocarcinoma
;
Chemoradiotherapy
;
Drug Therapy*
;
Humans
;
Maintenance Chemotherapy
;
Pancreatic Neoplasms*
;
Radiotherapy
5.Current status and future prospect of pharmacotherapy for pancreatic cancer.
Yun FANG ; Meng-Ru LAI ; Yu-Qing GE ; Guang-Ji ZHANG ; Ru-Bin CHENG
China Journal of Chinese Materia Medica 2019;44(8):1509-1516
Pancreatic cancer is the most common digestive tract tumor with an increasing incidence in recent years. The poor prognosis of pancreatic cancer is mainly because of the inability of detecting tumor at an early stage,its high potential for early dissemination,and its relatively poor sensitivity to chemotherapy. Most patients have lost the opportunity for surgery when they are diagnosed,which resulted in an urgent need for the development of more effective and safe therapies for pancreatic cancer. However,the current clinical cancer chemotherapy based on gemcitabine leads to poor prognosis in pancreatic patients. With the continuous research on the biological and cellular signaling pathways of pancreatic cancer,there have emerged a great many of novel agents,including new chemotherapeutic,targetable and immune-modulatory drugs,and some drugs have achieved encouraging results. Furthermore,as an alternative and supplementary method,traditional Chinese medicine has shown good application prospects in the field of pancreatic cancer treatment. This article reviews the current status of drug therapy for pancreatic cancer,summarizes the strength and weakness of existing therapeutic drugs in the application process,gives prospects of possible breakthroughs for the pharmacotherapy in the future,and provides certain new ideas and lessons for subsequent drug development.
Forecasting
;
Humans
;
Medicine, Chinese Traditional
;
Pancreatic Neoplasms
;
drug therapy
6.Adjuvant Therapy of Pancreatic Cancer
Journal of Digestive Cancer Report 2019;7(1):5-7
Pancreatic cancer is a lethal disease since curative resection is available in only 20% of patients at the initial diagnosis. Even after radical resection of the cancer, most patients experience recurrence. Therefore, many clinical trials have been attempted to prevent recurrence of pancreatic cancer. The key clinical studies about adjuvant therapy of pancreatic cancer and currently available regimens in Korea will be reviewed concisely according to the chemotherapy, radiation therapy, or both.
Diagnosis
;
Drug Therapy
;
Humans
;
Korea
;
Pancreatic Neoplasms
;
Recurrence
7.Arginine metabolism: a potential target in pancreatic cancer therapy.
Jin-Shou YANG ; Cheng-Cheng WANG ; Jiang-Dong QIU ; Bo REN ; Lei YOU
Chinese Medical Journal 2020;134(1):28-37
Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant disease, which has an extremely low survival rate of <9% in the United States. As a new hallmark of cancer, metabolism reprogramming exerts crucial impacts on PDAC development and progression. Notably, arginine metabolism is altered in PDAC cells and participates in vital signaling pathways. In addition, arginine and its metabolites including polyamine, creatine, agmatine, and nitric oxide regulate the proliferation, growth, autophagy, apoptosis, and metastasis of cancer cells. Due to the loss of argininosuccinate synthetase 1 (ASS1) expression, the key enzyme in arginine biosynthesis, arginine deprivation is regarded as a potential strategy for PDAC therapy. However, drug resistance develops during arginine depletion treatment, along with the re-expression of ASS1, metabolic dysfunction, and the appearance of anti-drug antibody. Additionally, arginase 1 exerts crucial roles in myeloid-derived suppressor cells, indicating its potential targeting by cancer immunotherapy. In this review, we introduce arginine metabolism and its impacts on PDAC cells. Also, we discuss the role of arginine metabolism in arginine deprivation therapy and immunotherapy for cancer.
Arginine/metabolism*
;
Argininosuccinate Synthase
;
Carcinoma, Pancreatic Ductal/drug therapy*
;
Cell Line, Tumor
;
Humans
;
Pancreatic Neoplasms/drug therapy*
8.Systemic Chemotherapy in Advanced Pancreatic Cancer.
Hee Seung LEE ; Seung Woo PARK
Gut and Liver 2016;10(3):340-347
Pancreatic cancer remains one of the most lethal cancers. These patients often have multiple symptoms, and integrated supportive care is critical in helping them remain well for as long as possible. Fluorouracil-based chemotherapy is known to improve overall survival (OS) by approximately 3 months, compared to the best supportive care alone. A 1997 study comparing gemcitabine and fluorouracil treatment of advanced pancreatic cancer patients showed an improvement in OS of 1 month in patients receiving gemcitabine. Over the next 10 years, multiple randomized studies compared single-agent gemcitabine with combination chemotherapy and showed no effective survival improvement. However, the addition of erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, was associated with a significant improvement in OS of approximately 2 weeks. However, adoption of this regimen has not been widespread because of its limited effect and added toxicity. Two clinical trials have recently prolonged OS in advanced pancreatic cancer patients by almost 1 year. The first compared FOLFIRINOX with gemcitabine alone, and was associated with a significant improvement in median survival. The second compared gemcitabine and nab-paclitaxel with gemcitabine alone, and was associated with improvements in OS. At present, these regimens are considered standard treatment for patients with good performance statuses.
Drug Therapy*
;
Drug Therapy, Combination
;
Fluorouracil
;
Humans
;
Pancreatic Neoplasms*
;
Receptor, Epidermal Growth Factor
9.Core signaling pathways and new therapeutic targets in pancreatic cancer.
Lei YOU ; Ge CHEN ; Yu-pei ZHAO
Chinese Medical Journal 2010;123(9):1210-1215
OBJECTIVEPancreatic cancer is a highly aggressive malignancy that has been resistant to treatment. Advances in cancer genetics have improved our understanding of this disease, but the genetics of pancreatic cancer remain poorly understood. A better understanding of the pathogenic role of specific gene mutations and core signaling pathways would propel the development of more effective treatments. The objective in this review was to highlight recent research that shows promise for new treatments for pancreatic cancer.
DATA SOURCESAll articles cited in this review were mainly searched from PubMed, which were published in English from 1993 to 2009.
STUDY SELECTIONOriginal articles and critical reviews selected were relevant to the molecular mechanisms of pancreatic cancer.
RESULTSDysregulation of core signaling pathways and processes through frequently genetic alterations can explain the major features of pancreatic tumorigenesis. New therapeutic targets based on recent research are emerging that hold promise for the future management of pancreatic cancer.
CONCLUSIONNew agents used in conjunction with standard radiotherapy and chemotherapy might help to overcome drug resistance by targeting multiple signaling pathways to induce responsiveness of pancreatic cancer cells to death signals.
Humans ; Pancreatic Neoplasms ; drug therapy ; metabolism ; radiotherapy ; Signal Transduction ; drug effects ; radiation effects
10.Role of Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer.
Korean Journal of Pancreas and Biliary Tract 2016;21(3):117-127
Surgical resection offers the only chance of cure for nonmetastatic exocrine pancreatic cancer. However, only 15 to 20 percent of patients have potentially resectable disease at diagnosis; approximately 40 percent have distant metastases, and another 30 to 40 percent have locally advanced unresectable tumors. Typically, patients with locally advanced unresectable pancreatic cancer have tumor invasion into adjacent critical structures, particularly the celiac and superior mesenteric arteries. The optimal management of these patients is controversial, and there is no internationally embraced standard approach. Therapeutic options include chemoradiotherapy or chemotherapy alone. While it is reasonable to restage and reevaluate the potential for resectability after neoadjuvant therapy, the frequency of a complete resection and long-term survival is low for patients who initially have categorically unresectable tumors. Others have disease that is categorized as "borderline resectable." While these patients are potentially resectable, the high likelihood of an incomplete resection has prompted interest in strategies to "downstage" the tumor or to increase the likelihood of a margin-negative resection prior to surgical exploration using neoadjuvant therapy. The rationale for neoadjuvant therapy is as follows. First, it is to improve the selection of patients for whom resection will not offer a survival benefit (i.e., those who rapidly progress to metastatic disease during preoperative therapy). Second, it is to increase rates of margin-negative resections, which is the major goal of surgery. Third, it is to start an early treatment of micrometastatic disease. Initial attempt at downstaging with chemotherapy, chemoradiotherapy, or a combination followed by restaging and surgical exploration in responders rather than upfront surgery is suggested.
Chemoradiotherapy
;
Diagnosis
;
Drug Therapy
;
Humans
;
Mesenteric Artery, Superior
;
Neoadjuvant Therapy*
;
Neoplasm Metastasis
;
Pancreatic Neoplasms*